Arrhythmia Research Technology‘s (NYSE:HRT) Signal-Averaged Electrocardiography device is 1 of only 2 ECG tests that can predict ventricular arrhythmias in patients with prior heart attacks, data from an NIH-funded multi-center clinical trial proves.
Geneva-based Endosense’s proprietary contact force technology improves efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, according to new study data released last week at the annual Heart Rhythm Society meeting.
Patients with Sorin Group (BIT:SRN) dual-chamber implantable cardioverter defibrillators had significantly fewer inappropriate shocks than patients with standard single-chamber devices, according to new clinical data.
Recent study data proves longer battery life of Boston Scientific‘s (NYSE:BSX) implantable cardiac defibrillators and cardiac resynchronization therapy defibrillators, helping keep patients out of the hospital and reduce risk of infections and complications, the company claimed last week.
This morning I sit quietly in my hotel room, contemplating the day ahead at the 2013 Heart Rhythm Society Scientific Sessions in Denver. Emotions clash.
Medical device giant St. Jude Medical (NYSE:STJ) landed an important win today after a research team released study results finding that the company’s Durata defibrillator leads proved safe and reliable in an independent review.
MassDevice Network
@MassDevice
LinkedIn
YouTube